CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it will effect a one-for-twenty (1:20) reverse stock split (the "Reverse Stock Split") of its common stock, par value $0.001 per share (the "Common Stock"). The Reverse Stock Split is expected to become effective on September 8, 2026, Eastern Time (the "Effective Time"), and the Common Stock is expected to